References
  1. DiPippo AJ, Rausch CR, Kontoyiannis DP. Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. Mycoses . 2019;62(1):81-6.
  2. Spellberg B, Rieg G, Bayer A, Edwards JE, Jr. Lack of cross-hepatotoxicity between fluconazole and voriconazole. Clin Infect Dis . 2003;36(8):1091-3.
  3. Foo H, Gottlieb T. Lack of Cross-Hepatotoxicity between Voriconazole and Posaconazole. Clin Infect Dis . 2007;45(6):803-5.
  4. Martínez-Casanova J, Carballo N, Luque S, Sorli L, Grau S. Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis. Infection Drug Resistance . 2018;11:317-21.
  5. Common Terminology Criteria for Adverse Events (CTCAE) Version 5 [Internet]. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
  6. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther . 1981;30(2):239-45.
  7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]: Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; [Available from: livertox.nih.gov/.
  8. Egunsola O, Adefurin A, Fakis A, et al. Safety of fluconazole in paediatrics: a systematic review. Eur J Clin Pharmacol . 2013;69(6):1211-21.
  9. Somchit N, Wong CW, Zuraini A, et al. Involvement of phenobarbital and SKF 525A in the hepatotoxicity of antifungal drugs itraconazole and fluconazole in rats. Drug Chem Toxicol . 2006;29(3):237-53.
  10. Haegler P, Joerin L, Krähenbühl S, Bouitbir J. Hepatocellular Toxicity of Imidazole and Triazole Antimycotic Agents. Toxicol Sci . 2017;157(1):183-95.
  11. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis . 2010;50(1):27-36.
Table I: Overview of patients with azole-induced hepatotoxicity whose liver functions tests improved after switching to another triazole antifungal